Over the course of the past year, the company has opened 14 new centers throughout the United States and acquired three additional centers.
RESEARCH TRIANGLE PARK, N.C. (February 13, 2008) — Talecris Plasma Resources, Inc., a wholly owned subsidiary of Talecris Biotherapeutics, Inc., (www.talecris.com) today provided insight into the company’s progress developing its plasma collection capabilities. Over the course of the past year, the company has opened 14 new centers throughout the United States and acquired three additional centers. As of January 2008, Talecris owns a total of 49 plasma collection centers, 33 licensed and 16 unlicensed. Also, five additional unlicensed centers supplying Talecris were opened in 2007 through Talecris’ strategic alliance with International BioResources, LLC. In addition, Talecris is in the process of automating all its plasma collection centers. As of January 2008, Talecris has automated 24 of its plasma collection centers.
“At Talecris, we have a long-term commitment to providing reliable supplies of the safest and most advanced protein therapeutics possible to our patients. The number of plasma centers Talecris is opening underscores this promise, and is unprecedented in our industry,” said Lawrence Stern, Chairman and CEO of Talecris Biotherapeutics, Inc. “In effect, we are growing as fast as we can while staying true to our guiding principles of quality and compliance.”
Talecris also made progress improving certain centers it obtained through acquisition. In 2007, Talecris received 10 new FDA licenses and completed 30 FDA inspections. In addition, the company has successfully remediated a center acquired late in 2006 that, at the time of acquisition, was operating with a warning letter from the FDA. Based on a recent FDA inspection of the center, which concluded with no observations from the FDA, the Warning Letter will be removed from the center.
Plasma collected at Talecris centers provides the source material for the production of critical care protein therapies to treat people with life-threatening disorders in a variety of therapeutic areas, including immunology, pulmonology and hemostasis. The current list of company-owned plasma collection center locations may be accessed at www.talecrisplasma.com/tpr_where.cfm.
Contact:
Lacy McMahon
Tel.: 919.316.6316, Fax: 919.316.6673
E-mail: lacy.mcmahon@talecris.com
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|